Entera Bio Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ENTX Nasdaq 2836 www.enterabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Entera Bio Ltd.

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation - Dec 31st, 2025 5:51 am
Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation - Dec 23rd, 2025 6:30 am
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program) - Dec 22nd, 2025 6:30 am
Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference - Nov 18th, 2025 6:00 am
Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates - Nov 14th, 2025 2:05 pm
Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women - Oct 23rd, 2025 6:50 am
Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting - Oct 16th, 2025 6:45 am
Individual investors are Entera Bio Ltd.'s (NASDAQ:ENTX) biggest owners and were rewarded after market cap rose by US$34m last week - Oct 11th, 2025 6:33 am
Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy - Sep 18th, 2025 6:41 am
Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress - Sep 15th, 2025 7:00 am
Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025 - Sep 8th, 2025 6:30 am
Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences - Aug 28th, 2025 6:00 am
Entera Bio Second Quarter 2025 Earnings: US$0.057 loss per share (vs US$0.058 loss in 2Q 2024) - Aug 11th, 2025 4:30 am
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates - Aug 8th, 2025 2:05 pm
OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results - Jul 31st, 2025 2:05 pm
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis - Jul 28th, 2025 5:30 am
OPKO Health’s (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX) - Jul 23rd, 2025 9:25 am
Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth - Jul 16th, 2025 12:31 pm
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress - Jul 8th, 2025 6:00 am
OPKO Health (OPK) to Present OPK-88006 Data at ENDO 2025 - Jun 29th, 2025 1:03 am